Antimicrobial Stewardship Program for Clostridium Difficile Infection.

CompletedOBSERVATIONAL
Enrollment

403

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

December 15, 2017

Study Completion Date

December 15, 2017

Conditions
Clostridium DifficileEnterocolitis, Pseudomembranous
Interventions
BEHAVIORAL

Systematic evaluation by an ID expert.

"Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."

Trial Locations (1)

28041

Unidad de Enfermedades Infecciosas. Hospital Universitario 12 de Octubre, Madrid

All Listed Sponsors
collaborator

Hospital Universitario 12 de Octubre

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

José María Aguado García, MD, PhD

OTHER

NCT02951481 - Antimicrobial Stewardship Program for Clostridium Difficile Infection. | Biotech Hunter | Biotech Hunter